CASTLE BIOSCIENCES INC (CSTL) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US14843C1053
CASTLE BIOSCIENCES INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 344.23 m USD |
| Gross profit | 273.20 m USD |
| Operating income | -42.81 m USD |
| EBIT | -41.20 m USD |
| Net income | -24.16 m USD |
| Diluted EPS – continuing operations | -0.83 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CASTLE BIOSCIENCES INC
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
More stocks
- Guomai Technologies Inc (002093.SZ)
- Darbond Technology Co. Ltd. A (688035.SS)
- Zhejiang Tianyu Pharmaceutical Co Ltd (300702.SZ)
- Heritage Insurance Holdings, Inc. (HRTG)
- POWER SOLUTIONS INTERNATIONAL, INC. (PSIX)
- Rio2 Ltd (RIO.V)
- Sumitomo Osaka Cement Co Ltd (5232.T)
- Berliner Effektengesellschaft (BFV.F)
- DAEHAN SHIPBUILDING LTD (439260.KS)
- Harbin Xinguang Optic Electronics (688011.SS)
- China Railway Tielong Container Logistics Co Ltd (600125.SS)
- Business First Bancshares, Inc. (BFST)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.